TScan Therapeutics (TCRX) Set to Release Earnings on Wednesday

TScan Therapeutics (NASDAQ:TCRX) is projected to post its Q3 2026 results before the market opens on Wednesday, November 11th. Analysts expect TScan Therapeutics to post earnings of ($0.18) per share and revenue of $0.46 million for the quarter. Individuals may review the information on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Wednesday, November 11, 2026 at 9:30 AM ET.

TScan Therapeutics (NASDAQ:TCRX) last announced its earnings results on Wednesday, August 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.02. The firm had revenue of $1.05 million for the quarter, compared to analysts’ expectations of $1.88 million. TScan Therapeutics had a negative net margin of 1,655.35% and a negative return on equity of 108.72%. On average, analysts expect TScan Therapeutics to post ($0.79) EPS for the current fiscal year and ($0.65) EPS for the next fiscal year.

TScan Therapeutics Price Performance

NASDAQ:TCRX opened at $0.20 on Wednesday. The firm has a market capitalization of $13.35 million, a price-to-earnings ratio of -0.20 and a beta of 1.21. The company has a debt-to-equity ratio of 0.31, a current ratio of 3.37 and a quick ratio of 3.37. The business has a 50 day simple moving average of $0.33 and a 200-day simple moving average of $0.84. TScan Therapeutics has a 1 year low of $0.17 and a 1 year high of $1.47.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the stock. HC Wainwright downgraded shares of TScan Therapeutics from a “buy” rating to a “neutral” rating and set a $1.00 target price on the stock. in a research note on Tuesday, September 8th. Benchmark reissued a “buy” rating on shares of TScan Therapeutics in a research note on Thursday, August 13th. Lifesci Capital lowered shares of TScan Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, September 2nd. Wedbush downgraded shares of TScan Therapeutics from a “buy” rating to a “neutral” rating and set a $1.00 target price for the company. in a report on Wednesday, September 2nd. Finally, Weiss Ratings cut TScan Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, September 8th. Two investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, TScan Therapeutics currently has an average rating of “Hold” and a consensus target price of $2.67.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc is a clinical-stage biotechnology company developing T cell receptor-engineered T cell (TCR-T) therapies for cancer. Its approach involves genetically modifying a patient’s T cells to recognize specific cancer-related antigens, with the goal of directing the immune system to attack malignant cells.

The company’s pipeline includes investigational therapies for hematologic malignancies and solid tumors. Its lead programs, TSC-100 and TSC-101, are designed to target the HA-1 antigen in patients with certain blood cancers following an allogeneic hematopoietic stem cell transplant.